Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
about
Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentBeyond BRAF: where next for melanoma therapy?Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondCIViC databaseIdentification of PLX4032-resistance mechanisms and implications for novel RAF inhibitorsKinase fusions are frequent in Spitz tumours and spitzoid melanomas.Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.Genotyping of cutaneous melanoma.Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaClinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.Activating MET kinase rearrangements in melanoma and Spitz tumours.TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencingGenomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapyPrimary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.The genomic landscape of cutaneous melanoma.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.A review of kinase fusions in melanocytic tumors.Kinase gene fusions in defined subsets of melanoma.Anaplastic Lymphoma Kinase in Cutaneous MalignanciesNTRK3 kinase fusions in Spitz tumoursMelanoma BRAF fusions--letter.Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.The genomic landscape of childhood and adolescent melanoma.Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.Primary and Metastatic Melanoma With NTRK Fusions.Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
P2860
Q26740631-CD467E23-5A9A-4C7D-AF21-2007B67BC904Q27006853-2155C3BD-319E-4E5D-B72A-68D4ED5339B6Q27026323-4FDEEFEB-910E-40CD-8A08-3ABD49510704Q27612411-DB49F3A5-5B46-4C78-87CF-73DFC879C211Q33784436-52255FB9-9841-40C8-9541-680ADBDE7051Q33854847-3118643D-CA60-43E8-BA2F-3C7F1C762378Q34052520-1B85934E-482E-46C3-A8F6-FB28663DA010Q34193749-E2D13A89-0C96-444E-9B19-24EABC8D41BDQ34556842-669ABDBD-30A1-4107-9C35-D155D4E43311Q34667738-CD38CF9D-6172-40C0-88FC-516E2EC80853Q34898560-54430568-3267-48A0-8BDF-3CDEF2DBF188Q35433876-2B83F8E0-A9A5-4D2B-AA7D-F5546F1C233EQ35658282-CB59F349-14D7-4417-8120-D236A7A85D0BQ35711083-1ADD03D4-5751-41D6-87ED-345D3F903F1AQ35963400-8ADCD887-F9A6-411E-ADE6-B133E129E486Q35995950-55D81ADB-0A91-4DB9-9C29-AC984DA11AF5Q36057564-D5C37EB0-C93D-4147-8B9D-0DA470A3F9ECQ36739466-BF829536-3311-40F1-A418-FD9EC56F3AB3Q36755569-0ABF9E08-B078-40BE-8BBE-E820D11D3AD2Q37286919-7919BBB4-BFC7-4DE1-B324-4398D7A0E367Q37308973-7A21FBF7-0D01-47E8-B33A-61E8F11B0E89Q37496876-B8083CB3-1F0A-48EA-901B-74C9FED474ECQ38718904-AD51140B-3E75-4D8E-AE43-F1126CCE83E9Q38856722-0BC8FE51-93CA-4C5D-AEF8-23BF19BB5B10Q38917480-FAE3A107-046E-445B-8742-77988E8257E7Q39022023-6A4F462E-27CF-4CD9-9C54-04940C865A8AQ39172703-74D24CC2-0CCA-4E25-AAF4-D9E021072C13Q41670874-39452CB5-8B4C-4F06-8145-F1B4371C64FAQ42709455-EB65D165-34B1-4D10-9313-A6C8501FA199Q43070386-FE62FBAE-0B0F-498D-ADA1-B90EB301FB92Q43084967-544595ED-EB97-4761-8C15-A23C1BB7622FQ43163168-A318F276-4502-4094-B5DB-D15FDB01E955Q47285585-12A172B5-ED9E-4130-8357-C7CC417D8A79Q47704002-1F853611-E528-4467-9B74-55017D271B22Q48240196-78A12128-9BE2-4D0B-B11B-714D8422CA1AQ52570211-14925AF3-A739-4164-AFD3-C1BB64562B6EQ52905583-2984115F-97B0-44EA-8DCA-3884B8CBF62B
P2860
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@ast
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@en
Recurrent BRAF kinase fusions ...... ortunity for targeted therapy.
@nl
type
label
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@ast
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@en
Recurrent BRAF kinase fusions ...... ortunity for targeted therapy.
@nl
altLabel
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@en
prefLabel
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@ast
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@en
Recurrent BRAF kinase fusions ...... ortunity for targeted therapy.
@nl
P2093
P2860
P50
P3181
P356
P1476
Recurrent BRAF kinase fusions ...... portunity for targeted therapy
@en
P2093
Alyssa Sparatta
Elizabeth A Burton
Gideon Bollag
Maria C Garrido
Maryline Allegra
Philip E LeBoit
Stephane Rocchi
Swapna S Vemula
Timothy H McCalmont
Tyrrell Nelson
P2860
P304
P3181
P356
10.1111/PCMR.12148
P577
2013-08-19T00:00:00Z